Chapter 3 – Breast Cancer

Breast cancer is the most common type of invasive cancer and the second cause of cancer-related death in women. In addition to clinical information, benign findings and pitfalls in fludeoxyglucose (FDG) PET/CT reading, and teaching cases, this chapter reviews evidence-based recommendations regarding PET/CT examination in breast cancer and compares them with statements in major clinical guidelines. According to evidence-based data, FDG PET/CT can potentially replace conventional imaging modalities in staging of locally advanced breast cancer and is recommended for the evaluation of response to chemotherapy or radiation therapy. Interestingly, FDG uptake is higher in patients with triple-negative or HER2-positive malignant lesions and inversely correlates with prognosis.

[1]  P A Salvadori,et al.  Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. , 2000, Clinical breast cancer.

[2]  P. Conte,et al.  Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment? , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  Thomas J. Smith,et al.  Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  E. Rutgers,et al.  Evaluation of a Hanging-Breast PET System for Primary Tumor Visualization in Patients With Stage I-III Breast Cancer: Comparison With Standard PET/CT. , 2016, AJR. American journal of roentgenology.

[5]  E. Gontier,et al.  18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer , 2015, The Journal of Nuclear Medicine.

[6]  Yiyan Liu.  Role of FDG PET-CT in evaluation of locoregional nodal disease for initial staging of breast cancer. , 2014, World journal of clinical oncology.

[7]  D. Hendler,et al.  Uncommon reason for high fluorodeoxyglucose positron emission tomography uptake. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Schnitt,et al.  Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy , 2010, Modern Pathology.

[9]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[10]  R. A. Valdés Olmos,et al.  Molecular Imaging in Breast Cancer: From Whole-Body PET/CT to Dedicated Breast PET , 2012, Journal of oncology.

[11]  A. Alavi,et al.  False-Negative and False-Positive Results in FDG-PET and PET/CT in Breast Cancer. , 2009, PET clinics.

[12]  V. Dilsizian,et al.  SNMMI/ASNC/SCCT Guideline for Cardiac SPECT/CT and PET/CT 1.0* , 2013, The Journal of Nuclear Medicine.

[13]  B. Kang,et al.  The value of primary tumor 18F-FDG uptake on preoperative PET/CT for predicting intratumoral lymphatic invasion and axillary nodal metastasis , 2016, Breast Cancer.

[14]  Mithat Gonen,et al.  18F-FDG PET of Locally Invasive Breast Cancer and Association of Estrogen Receptor Status with Standardized Uptake Value: Microarray and Immunohistochemical Analysis , 2010, Journal of Nuclear Medicine.

[15]  Radiation safety with positron emission tomography and computed tomography. , 2010, Seminars in ultrasound, CT, and MR.

[16]  Sanjiv S Gambhir,et al.  FDG-PET and beyond: molecular breast cancer imaging. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Bhattacharya,et al.  Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma , 2012, Nuclear medicine communications.

[18]  A. Glas,et al.  Impact of mammographic screening on the detection of good and poor prognosis breast cancers , 2011, Breast Cancer Research and Treatment.

[19]  W. Oyen,et al.  Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  B R Rosen,et al.  Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients , 2015, British Journal of Cancer.

[21]  M. Blaufox,et al.  A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases , 2005, Breast Cancer Research and Treatment.

[22]  Alexandre Cochet,et al.  Role of positron emission tomography for the monitoring of response to therapy in breast cancer. , 2015, The Oncologist.

[23]  M. Gonen,et al.  Retrospective Analysis of 18F-FDG PET/CT for Staging Asymptomatic Breast Cancer Patients Younger Than 40 Years , 2014, The Journal of Nuclear Medicine.

[24]  J. Vercher-Conejero,et al.  Positron Emission Tomography in Breast Cancer , 2015, Diagnostics.

[25]  S. Kwon,et al.  Correlation of Primary Tumor FDG Uptake with Clinicopathologic Prognostic Factors in Invasive Ductal Carcinoma of the Breast , 2015, Nuclear Medicine and Molecular Imaging.

[26]  S. Rodenhuis,et al.  Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy , 2012, Breast Cancer Research and Treatment.

[27]  J. Brade,et al.  18 F-FDG PET/CT for initial staging in breast cancer patients – Is there a relevant impact on treatment planning compared to conventional staging modalities? , 2015, European Radiology.

[28]  W Bolch,et al.  ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances , 2015, Annals of the ICRP.

[29]  D. Mankoff,et al.  18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Groheux,et al.  18F-FDG PET/CT in Staging Patients with Locally Advanced or Inflammatory Breast Cancer: Comparison to Conventional Staging , 2013, The Journal of Nuclear Medicine.

[31]  M. Piccart,et al.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  P. Goss,et al.  Estrogen and the risk of breast cancer. , 2001, The New England journal of medicine.

[33]  S. Mattsson,et al.  Excretion of radionuclides in human breast milk after nuclear medicine examinations. Biokinetic and dosimetric data and recommendations on breastfeeding interruption , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  K. Kang,et al.  Correlation between 18F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer , 2015, European Radiology.

[35]  S Leide-Svegborn,et al.  Radiation exposure of patients and personnel from a PET/CT procedure with 18F-FDG. , 2010, Radiation protection dosimetry.

[36]  I. Fogelman,et al.  The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. , 2006, Seminars in nuclear medicine.

[37]  David A Mankoff,et al.  FDG PET, PET/CT, and breast cancer imaging. , 2007, Radiographics : a review publication of the Radiological Society of North America, Inc.